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ABSTRACT 
 
High Mobility Group A1 (HMGA1) is a chromatinic protein whose overexpression is 
a feature of malignant neoplasias. Many studies support its causal role in cell 
transformation and cancer progression. Indeed, HMGA1 is an architectural 
transcriptional factor that regulates, by binding DNA and interacting with various 
transcriptional regulators, the expression of several genes involved in critical 
biological processes, such as cell proliferation, apoptosis and migration. Autophagy is 
a self-degradative process that, providing energy sources, removing damaged 
organelles and misfolded or aggregated proteins, allows cell survival in stress 
conditions or, when iper-activated, leads to non-apoptotic programmed cell death. 
Autophagy is often deregulated in cancer cells in which plays an important and 
complex role, being mainly oncogenic during cancer initiation, and tumor-
suppressive during cancer progression. Studying the effects of HMGA1 knock-down 
in skin cancer cells SCC-13, I have found that it increases autophagy, as assessed by 
both western blot and immunofluorescence analysis of several autophagic markers, 
such as pS6, LC3 and SQSTM1/p62. Interestingly, the ability of HMGA1 depletion 
to increase autophagy is not restricted to skin cancer cells, since similar results have 
been achieved also silencing HMGA1 expression in HeLa cells, and mouse 
embryonic fibroblasts null for Hmga1 are more susceptible than the wild-type 
counterpart to undergo autophagy after starvation or treatment with rapamycin. 
Consistently, silencing of HMGA1 upregulates the two autophagy-initiating kinases 
Unc-51-like kinase 1 (ULK1) and Unc-51-like kinase 2 (ULK2), and functional 
experiments demonstrate that HMGA1 binds their promoter regions and negatively 
regulates their transcription. Accordingly, the block of ULK1 expression reduces the 
pro-autophagic effects induced by HMGA1 silencing indicating that they are, at least 
in part, mediated by ULK1. Taken together, these results clearly indicate that 
HMGA1 protects cancer cells from autophagy, thus suggesting, on one hand, a new 
mechanism through which HMGA1 can contribute to cancer progression and, on the 
other hand, a mechanism through which autophagy can be deregulated in cancer cells. 
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1.Introduction 
1.1 HMGA proteins 
The High Mobility Group (HMG) family is composed by 
heterogeneous chromatin non-histone proteins with the common feature of 
being smaller than 30 kDa (so they have an “high mobility” in electrophoresis 
gels) and rich in both acidic and basic amino acids. In mammals HMG proteins 
have been classified into three distinct sub-families: HMGB (formerly HMG-
1/-2), HMGN (formerly HMG-14/-17) and HMGA (formerly HMG-I/-Y/-C). 
The characteristic functional motifs of HMGB, HMGN and HMGA sub-
families are the “HMG-box”, the “nucleosomal binding domain” and the “AT-
hook” respectively. HMGB and HMGN proteins are involved in development 
(Furusawa and Cherukuri 2010) and HMGB proteins play also an important 
role in inflammation and innate immune response (Yanai et al. 2009). HMGA 
proteins are involved in many biological process such as development, cell 
growth, differentiation, apoptosis and cancer. This sub-family is composed of 
four proteins: HMGA1a (Johnson et al. 1989), HMGA1b (Friedamnn et al. 
1993), HMGA1c (Nagpal et al. 1999) and HMGA2 (Chau et al. 1995) 
(formerly HMGI, HMGY, HMG-I/R and HMGI-C respectively). They are 
encoded by two distinct genes: HMGA1 and HMGA2. HMGA1 encodes 
HMGA1a5, HMGA1b6 and HMGA1c through alternative splicing, whereas 
HMGA2 encodes HMGA2. In addition, there are also numerous conserved 
pseudogenes in both mice and humans (De Martino et al. 2016). 
The HMGA proteins are characterized by small size (10.6-12 kDa), 
solubility in dilute acids, high concentration of basic, acidic and proline amino 
acids, rapid mobility electrophoresis and by the ability to bind to the minor 
groove of short AT-rich DNA stretches (Lund et al. 1983). Spectroscopic 
techniques, such as circular dicroism and nuclear magnetic resonance 
spectroscopy, indicated that the HMGA proteins, as free molecules, had very 
little, if any, secondary structure. Nevertheless, when bound to other 
molecules, such DNA or protein substrates, the HMGA proteins assume 
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defined structural features (Reeves et al. 1987, Lehn et al. 1988). The HMGA 
proteins undergo a lot of different post-translational modifications 
(phosphorylation, acetylation, methylation and poly-ADP-ribosylation) which 
are dynamic and rapidly responding to both intra- and extracellular signaling 
events (Reeves and Beckerbauer 2001). These modifications also influence 
both the substrate-binding properties of the HMGA proteins and their 
biological activities. For example Cdc2 and Homeodomain-Interacting Protein 
Kinase 2 (HIPK2) phosphorylate HMGA1 resulting in a decrease in DNA 
binding (Zhang and Wang 2007).  
The structure of each HMGA protein is characterized by three N-
terminal AT-hook domains and a C-terminal domain involved in protein-
protein interactions (see figure 1.1). The AT-hook domains display the 
consensus sequence of Pro-Arg-Gly-Arg-Pro flanked on either side by a 
number of positively charged lysine/arginine residues. The core of AT-hook 
motif is highly conserved in evolution and is also found in a large number of 
other, non-HMGA, proteins, especially transcription factors or components of 
chromatin remodeling complexes (Aravind and Landsman 1998). The HMGA 
proteins recognize DNA structure (rather than nucleotide sequences) like bent 
and supercoiled DNAs (Nissen and Reeves 1995, Bustin and Reeves 1996), 
synthetic fourway junctions (Hill et al. 1999), base-unpaired regions of AT-
rich DNA (Liu et al. 1999) and restricted regions of DNA on the surface of 
nucleosomal core particles (Reeves and Nissen 1993). HMGA binding can 
induce structural changes in bound DNA substrates. Depending on the 
sequence, the organization, the topology or the length of the substrates, HMGA 
binding can bend, straighten, unwind and induce looping in linear DNA 
molecules (Esposito 2008). Exerting their role of architectural transcription 
factors, HMGA proteins also participate in protein-protein interactions and 
induce structural changes in protein substrates, many of which are gene 
regulatory factors. 
! 11!
 
 
Figure 1.1 Schematic representations of HMGA1 and HMGA2 genes and HMGA1 and 
HMGA2 proteins. Each protein contains three basic domains, named AT hook (green box), 
with which they bind DNA, and an acidic carboxy-terminal region (red box) involved in 
protein-protein interactions (image from Fusco and Fedele 2007). 
 
1.1.1 HMGA proteins regulate chromatin remodeling and gene expression 
Chromatin structure plays a fundamental role in the regulation of gene 
expression in eukaryotic cells. Chromatin may exert a repressive effect on gene 
transcription, if either nucleosomes or other inhibitory chromatin proteins (as 
histone H1) are associated with critical regulatory regions of gene promoters or 
enhancers. Elaborate mechanisms, such as ATP-dependent chromatin 
remodeling machines, as well as precisely controlled biochemical 
modifications of histones and other regulatory protein complexes, have 
evolved to alter or modulate such repressive chromatin structures and allow 
active gene transcription (Fry and Peterson 2001). 
HMGA proteins participate in gene expression regulation through 
different mechanisms. Even though they have not transcriptional activity per 
se, HMGA proteins act as architectural transcription factors, by interacting 
with the transcription machinery, altering chromatin structure and thereby 
regulating, negatively or positively, the transcriptional activity of several genes 
(Thanos and Maniatis 1992, Thanos and Maniatis 1993). In particular, HMGA 
proteins can modify DNA conformation and/or chromatin structure facilitating 
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the binding of several transcriptional factors. For example, HMGA proteins 
mediate the formation of an “enhanceosome”, a stereo-specific, multi-protein 
complex that includes HMGA proteins and other transcription factors making 
specific protein-DNA and protein-protein contacts in intricate but precise ways 
(Merika and Thanos 2001). The HMGA proteins can also influence gene 
transcription through direct protein-protein interactions with transcription 
factors by modifying their conformation and enhancing their binding affinity 
for DNA (see figure 1.2). When HMGA proteins act as negative regulators of 
gene expression, they often serve as inhibitors of enhanceosome formation, 
usually by sterically blocking the functional binding of other crucial 
transcription factors to their recognition sites in gene promoters (Esposito 
2008). 
There are reports of more than 60 different eukaryotic and viral genes 
whose transcriptional expression is regulated by HMGA proteins in vivo 
(Reeves and Beckerbauer 2001, Martinez Hoyos et al. 2004). The promoter 
regions of many of the regulated genes contain multiple stretches of AT-rich 
sequences that have been proposed to represent a gene-specific ”bar code” that 
is “read” by the AT-hooks during the process of transcriptional regulation. 
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Figure 1.2 Mechanisms of action of HMGA proteins. The HMGA proteins participate in 
assembly or modulation of macromolecular complexes involved in the regulation of gene 
expression. In doing so, HMGA proteins directly bind the DNA, modifying its conformation 
and consequently facilitating the binding of a group of transcriptional factors (TF). HMGA 
proteins a) interact with both DNA and TFs to generate a multiprotein stereospecific complex 
bound to DNA; b) can influence gene transcription through direct protein-protein interactions 
with a TF by modifying its conformation and enhancing its DNA binding affinity or c) alter the 
chromatin structure (image from Fusco and Fedele 2007). 
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1.1.2 HMGA proteins are overexpressed in cancer cells 
HMGA genes are physiologically expressed during embryogenesis at 
high levels in almost all tissues, whereas their expression is absent or low in 
adult healthy tissues. However the expression of both HMGA genes is high in 
malignant cells in vitro and in vivo, and it is clearly demonstrated that these 
genes play an important role in carcinogenesis (Fusco and Fedele 2007). The 
correlation between HMGA proteins and the neoplastic phenotype first 
emerged when two-dimensional electrophoresis found changes in nuclear 
proteins following the transformation of a rat thyroid cell line (FRTL5) by the 
Kirsten murine sarcoma virus (KiMSV) (Giancotti et al. 1985). The expression 
of HMGA1a, HMGA1b and HMGA2 was observed after cellular 
transformation. Subsequent studies validated the association of these proteins 
with high malignant phenotype and indicate that HMGA proteins have 
oncogenic activities, being causally involved in neoplastic transformation. 
When FRTL5 cells were transfected with an antisense construct against 
HMGA2 or against HMGA1 and then infected with KiMSV, they expressed 
significant levels of retroviral oncogene (v-ras-Ki) but did not grow in soft agar 
or form tumors in athymic mice. Other studies demonstrate that HMGA1a, 
HMGA1b or HMGA2 transforms rat fibroblast and human lymphoblastoid 
cells (Berlingieri et al. 1995, Berlingieri et al. 2002). Moreover it has been 
observed that transgenic mice over-expressing the wild type form of HMGA1 
gene develop mixed growth hormone/prolactin cell pituitary adenomas and 
natural killer cell lymphomas (Fedele et al. 2005). 
The induction of the HMGA genes in malignant transformation 
probably occurs through oncofetal transcriptional mechanisms which have not 
yet been well characterized. It is known that the elevated expression of 
HMGA1 in cancer cells requires a complex cooperation between SP1 family 
members and AP1 factors, induced by the activation of Ras GTPase signaling 
(Cleyen et al. 2007). Even though the molecular basis of HMGA genes 
upregulation are not fully understood so far, we know that they may change 
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among different tumour types, and may involve chromosomal rearrangements, 
micro-RNAs (miRNAs) and competitive endogenous-RNAs (ceRNAs) (De 
Martino et al. 2016). 
Chromosomal rearrangements involving HMGA1 or HMGA2 genes 
have been found in a lot of different human benign tumor (expecially of 
mesenchymal origin). In particular lipomas, uterine leiomyomas, 
fibroadenomas of the breast, endometrial polyps, pleomorphic adenomas of the 
salivary glands and pituitary adenomas express a rearranged HMGA2 gene 
coding for a chimeric or a truncated protein that maintains its ability to bind 
DNA and interact with several proteins, but loses its carboxy-terminus, 
including the 3’ untranslated region (3’UTR). Among the HMGA2 fusion 
partners, tumor-suppressor genes have been described (FHIT, RAD51L1 and 
HEI10). In all of these cases, the rearrangement of the partner gene results in a 
loss of function of the protein encoded by the tumor-suppressor gene itself, in 
addition to HMGA2 overexpression (Fusco and Fedele 2007). The expression 
of a truncated or chimeric form of HMGA2 causes malignant transformation of 
NIH3T3, conversely wild-type HMGA2 did not transform cells. This 
difference is probably due to the absence of 3’UTR in truncated or chimeric 
forms of HMGA2. Without 3’UTR these forms can avoid the negative 
regulation of miRNAs which normally targets HMGA2 (let-7 and miRNA-98) 
(Lee et al. 2007, Hebert et al. 2007). In addition to HMGA2, rearrangements of 
HMGA1 gene have been frequently described in benign human tumors 
(including lipomas, uterine leyomiomas, pulmonary chondroid hamartomas, 
and endometrial polyps), but no intragenic rearrangements have been found 
(Tallini et al. 2000). 
In malignant tumors HMGA proteins are expressed at high levels. In 
particular, HMGA 1 is expressed in all neoplastic tissues analyzed, including 
pancreas, thyroid, colon, breast, lung, ovary, uterine cervix and body, prostate 
and gastric carcinomas (Fusco and Fedele 2007). HMGA1 is expressed also in 
some form of leukaemia (see table 1.3). Importantly, overexpression of 
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HMGA1 correlated with malignancy and especially with metastatic ability, 
resistance to anti-cancer therapies and reduced survival. Indeed HMGA1 
expression gradually increases from benign astrocytoma to the malignant 
glioblastoma. So HMGA1 expression might be a candidate biomarker for 
cancer diagnosis and prognosis (Pallante et al. 2015).  
Recently, several studies reported a strong HMGA regulation by 
miRNAs in pituitary adenomas (mir-15, mir-16, miR-34b, mir-214, miR-326, 
miR-432, miR-548c- 3p, miR-570, miR-603 and mir-761), in thyroid 
carcinomas (let-7), and in breast cancer (mir-26a, miR- 33b). In addition, it is 
emerging that some HMGA-pseudogenes may “protect” HMGA transcripts 
from the inhibitory effects of these miRNAs by competing for the same 
miRNAs, acting as competitive ceRNAs (De Martino et al. 2016).  
 
 
Table 1.3 Cancers associated with aberrant expression of HMGA protein (table from 
Esposito 2008). 
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1.1.3 Oncogenic activity of HMGA1 
Several mechanisms have been proposed to account for the transforming 
ability of HMGA proteins and most of them are based on the ability of these 
proteins to regulate the expression of genes that have a crucial role in the 
control of cell proliferation and invasion. For example, HMGA1 proteins 
increase the activity of several members of AP-1 transcription factors family 
(like JUNB and FRA1) which play an important role in the regulation of cell 
proliferation, tumorigenesis and metastasis (Angel et al. 1991). HMGA1 also 
enhance the transcriptional activity of NF-kB causing the expression of 
inflammatory proteins (iNOS, COX2, E-selectin, IL-2, IL-4 and GMCSF) and 
is demonstrated that inflammation represents a risk factor for most types of 
cancer (Mantovani et al. 1998). Moreover HMGA protein overexpression 
impairs DNA repair negatively modulating the expression of some genes 
involved in this process (for example ERCC1) and because they compete with 
p53 and human MutS homologue proteins for Holliday junction binding, 
exerting a negative influence on the DNA mismatch repair response 
(Subramanian et al. 2002). HMGA1 interacts with p53 and interferes with p53-
mediated transcription of genes involved in regulation of apoptosis (BAX, 
BCL2) and cell cycle (CDKN1A) but promotes the transcription of the p53 
inhibitor MDM2 (Esposito et al. 2010), reducing p53-dependent apoptosis. 
Moreover, the overexpression of HMGA1 promotes the reduction of Brn-3a 
binding to the BCL2 promoter, thereby blocking the Brn-3a co-repressor 
function on BCL-2 expression following p53 activation (Esposito et al. 2010). 
HMGA1 alters the expression of genes involved in epithelial-mesenchymal 
transition (EMT) which is a common phenomenon in epithelial tumors 
(epithelial cells de-differentiate to a fibroblast-like state and regain the ability 
to invade, migrate and/or proliferate in an uncontrolled fashion) (Reeves et al. 
2001). 
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1.1.4 HMGA1 and chromosome instability 
Recently, we have identified a new mechanism by which HMGA1 
exerts its oncogenic activity: the induction of chromosome instability (CIN) 
through the de-regulation of Spindle Assembly Checkpoint (SAC) genes 
(Pierantoni, Conte et al. 2015, Pierantoni, Conte et al 2016). 
Genome instability, whose prominent form is represented by CIN, is a 
hallmark of cancer cells. CIN renders cancer cells prone to accumulate 
karyotypic alterations, such as gain or loss of whole chromosomes, 
translocation/deletion/duplication of chromosome segments or polyploidy. 
Alterations in chromosome number or aneuploidy can easily unbalance the 
equilibrium between oncogenes and tumour-suppressor genes, and are found in 
nearly all major human tumor types (Mertens et al. 1994). CIN is a feature 
often acquired by cancer cells during cancer progression, and is generally 
associated with the most aggressive forms of cancer. In cancer cells, one of the 
most frequent causes of CIN is the impairment of the SAC, the mechanism that 
prevents the anaphase onset until all chromosomes are attached with the proper 
amphitelic orientation to the mitotic spindle (Hartwell and Kastan 1994) (see 
figure 1.4). Interestingly, mutations of the genes coding for SAC proteins are 
quite rare in human cancers (reviewed by Rao et al. 2009), whereas their 
deregulation is more frequent, and it is widely demonstrated that both 
upregulation and downregulation of SAC genes can cause a checkpoint 
impairment leading to CIN. Indeed, downregulation of Bub1 expression has 
been detected in a subset of acute myeloid leukemia (Lin et al. 2002), whereas 
upregulation of Bub1 levels has been reported in lymphomas (Alizadeh et al. 
2000), breast (van’t Veer et al. 2002) and gastric cancers (Grabsch et al. 2003, 
Shigeishi et al. 2001). The molecular mechanisms of SAC genes regulation and 
de-regulation are almost still unknown.  
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Figure 1.4 Schematic model of SAC. Cells with an unsatisfied checkpoint recruit BUB1, 
BUBR1, BUB3, MAD1, MAD2 and CDC20 to unattached kinetochores. An inactive open-
MAD2 conformation is catalytically converted to a closed-MAD2 conformation that is able to 
bind to CDC20. The MAD2-CDC20 association prevents loss of cohesion of bi-oriented sister 
chromatids because it triggers the recruitment of BUBR1-BUB3 into an APC/C inhibitory 
complex. The function of SAC is linked to kinetochore-microtubule network through the 
physical interaction of BUB1 and BUBR1 with blinkin. In metaphase, when the checkpoint is 
satisfied (i.e. all chromosomes undergo bipolar attachment and are aligned at the center of the 
cell) it releases APC/C-CDC20 inhibition. Securin can be ubiquitylated by APC/C and 
degraded. This leads to the release and activation of separase that cleaves cohesin, the 
molecule that holds sister chromatids together at the centromere. The cleavage of cohesin at 
centromeres and chromosome arms is followed by chromosome separation and mitotic 
progression from metaphase to anaphase (image from Bolanos-Garcia and Blundell 2010).   
! 20!
We have demonstrated that HMGA1 increases the expression of Bub1, 
Bub1b, Mad2l1 and Mps1/Ttk SAC genes at both mRNA and protein level, 
binding their promoter regions and increasing their transcriptional activity. We 
have found that HMGA1 knock-down compromises the mitotic checkpoint 
activity, and that HMGA1-depleted cells show a higher percentage of 
metaphases with unaligned chromosomes and reduced pro-metaphase time 
compared to control cells. The correlation between HMGA1 and SAC genes 
expression was confirmed in human tumor samples. In fact, human colon 
carcinomas show high SAC gene expression that correlates with HMGA1 
levels, and this correlation further increases in liver metastasis of colon 
carcinomas (Pierantoni, Conte et al. 2015). 
In mouse embryonic fibroblasts (MEFs), that physiologically express 
HMGA1, the genetic ablation of HMGA1 gene causes down-regulation of SAC 
genes associated to features of CIN, such as nuclear abnormalities, bi-
nucleation, micronuclei and karyotypic alterations (Pierantoni, Conte et al. 
2016). 
On the basis of these findings, HMGA1 emerges as an important factor 
for both physiological SAC genes regulation in embryonic development, and 
their pathological de-regulation in cancer cells. 
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1.2 Autophagy 
The term ‘autophagy’ derives from the Greek, meaning ‘eating of self’, 
and was first coined over 40 years ago by Christian de Duve, who observed 
degradation of several cellular components within lysosomes of rat liver 
perfused with the pancreatic hormone glucagon (Deter et al. 1967). Nowadays, 
this term refers to a self-degradative process that provides energy sources in 
response to nutrient starvation, removes misfolded or aggregated proteins, 
cleare damaged organelles, and eliminates intracellular pathogens (Levine and 
Kroemer 2008). Autophagy plays a key role during embryonic development 
and tissue homeostasis, and it is generally considered a survival mechanism, 
although its deregulation may lead to non-apoptotic cell death. Moreover, 
autophagy has been linked to cellular senescence, antigen presentation, 
protection from genome instability and prevention of necrotic cell death, giving 
it a key role in the pathogenesis of several diseases, such as cancer, 
neurodegeneration, cardiomyopathy, diabetes, liver disease, autoimmune 
diseases and infections (Glick et al. 2010).  
The main feature of autophagy is the proteolytic degradation of 
cytosolic components at the lysosome, and, basing on the mechanism by which 
the cargo reaches the lysosome, we distinguish three different types of 
autophagy: macro-autophagy, micro-autophagy, and chaperone-mediated 
autophagy. Macro-autophagy is the most common and best characterized form 
of autophagy, so that the term “autophagy” usually refers to macro-autophagy. 
During this process, cytoplasmic cargo is delivered to the lysosome through a 
double membrane-bound vesicle, the so-called “autophagosome”, that fuses 
with the lysosome to form an “autophagolysosome” or “autolysosome”; 
whereas, in micro-autophagy, cytosolic components are directly taken up by 
the lysosome itself through invagination of its membrane. Both macro-and 
micro-autophagy are able to engulf large structures through both selective and 
non-selective mechanisms (Glick et al. 2010). By contrast, chaperone-mediated 
autophagy (CMA) is a selective process in which target proteins are bound by 
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chaperones (such as Hsc-70) that mediate their translocation across the 
lysosomal membrane interacting with the lysosomal membrane receptor 
lysosomal-associated membrane protein 2A (LAMP-2A) (Saftig et al. 2008). 
After lysosomal degradation, permeases and transporters export amino acids 
and other products of degradation back to the cytoplasm, where they can be re-
used for building macromolecules and for metabolism (Mizushima 2007) (see 
figure 1.5). Thus, autophagy may be considered a cellular ‘recycling factory’ 
that represents an energy support through ATP generation and mediates 
damage control by removing non-functional proteins and organelles. 
 
Figure 1.5 Schematic representation of macroautophagy (a), chaperone-mediated 
autophagy (b), and microautophagy (c) (image from Boya et al. 2013). 
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 Genetic screenings in the budding yeast Saccaromyces cerevisiae have 
conducted to the identification of 32 different autophagy-related genes (Atg), 
coding for the components of the autophagic molecular machinery, that are 
highly conserved in plants, worms, flies and mammals, underlining the 
importance of autophagy during evolution (Nakatogawa et al. 2009). This 
machinery orchestrates at molecular level the different steps of autophagy. The 
first step of autophagy consists in the isolation of a membrane, the phagophore, 
deriving from lipid bilayer of the endoplasmic reticulum (ER) and/or of the 
trans-Golgi and endosomes, that expands to engulf intra-cellular cargo, such as 
protein aggregates, organelles and ribosomes (Hayashi-Nishino et al. 2009). 
The phagophore formation, regulated by the energy-sensing mTOR kinase, is 
not well characterized in mammalian cells, but we know that it involves the 
kinases ULK-1 and ULK-2 (two homologues of the yeast Atg1), the class III 
PI-3 kinase vesicular protein sorting 34 (Vps34), and its interactor 
Atg6/Beclin-1 (Kundu et al. 2008, Liang et al. 1999). In response to starvation 
signaling, Beclin-1 promotes the catalytic activity of Vps34, increasesing the 
levels of PI3P and promoting the formation of the phagofore (Backer 2008). 
The interaction between Vps34 and Beclin-1 is modulated by several other 
proteins to either promote autophagy, such as UVRAG, BIF-1, Atg14L and 
Ambra (Liang et al. 2006, Fimia et al. 2007), or to inhibit it, such as Rubicon 
and BCL-2 (Matsunaga et al. 2009, Pattingre et al. 2005).  
The phagophore extention is mediated by the Atg5–Atg12–Atg16L 
complex, whose assembly requires the E1-ubiquitin activating enzyme Atg7 
and the E2-like ubiquitin carrier Atg10. The Atg5–Atg12–Atg16L complex 
induces curvature into the growing phagophore through asymmetric 
recruitment of processed microtubule-associated protein light chain 3 (LC3), 
the mammalian homologue of Atg8 (Glick et al. 2010). In basal conditions, 
LC3 is a cytosolic protein that, upon induction of autophagy, undergoes a 
multi-step processing culminating in its recruitment at the autophagosome 
membrane. LC3 is first cleaved by Atg4, a cysteine protease, to generate LC3-
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I, then activated in an ATP-dependent manner by Atg7, transferred to the E2-
like carrier protein Atg3, and then conjugated to phosphatidylethanolamine 
(PE) to generate LC3-II, that is recruited to both the internal and external 
surfaces of the autophagosome. LC3-II is thought to be one of the molecular 
determinants of the selectivity of the autophagic process. In fact, it may act as a 
‘receptor’ at the phagophore, promoting selective cargo uptake via interaction 
with ‘adaptor’ molecules that are bound to the targets (Kaminskyy and 
Zhivotovsky 2011). The most important adaptor protein, that interacts with 
LC3-II, is p62/SQSTM1, a multi-functional adaptor molecule that promotes 
turnover of poly-ubiquitinated protein aggregates, mediating their 
incorporation in autophagosomes. p62/SQSTM1 is mutated in the Paget's 
disease, in which abnormal turnover of bone results in bone deformation, 
arthritis and nerve injury (Ralston et al. 2008).  
The fusion of the autophagosome with the lysosome is the final step of 
autophagy and it is still poor characterized. It has been described that this step 
involves the small G protein Rab7 (Jager et al. 2004), the Alzheimer's disease 
Presenilin protein (Eskelinen 2005) and the microtubules cytoskeleton (Webb 
et al. 2004) Moreover, there is evidence that autophagosomes can fuse with 
early and late endosomes, prior to fusion with the lysosome (Eskelinen 2005).  
 
1.2.1 Signaling pathways that regulate autophagy 
During nutrient deprivation, autophagosome formation is dramatically 
induced. In both yeast and mammalian cells, two well-characterized signaling 
cascades that sense nutrient status, activate cell division and growth, and 
negatively regulate autophagy are the target of rapamycin (TOR) and Ras-
cAMP-PKA pathways (He and Klionsky 2009). TOR kinase is the major 
player in nutrient sensing and in regulating cell growth and autophagy; its 
activity is regulated by ATP levels, hypoxia, growth factor receptors and 
insulin signaling. In particular, in the presence of normal nutrients 
concentration, mammalian TOR (mTOR) is activated downstream of AKT 
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kinase, PI3-kinase and growth factor receptors, inhibiting autophagy and 
promoting cell growth, through induction of ribosomal protein expression and 
increased protein translation (see figure 1.6). The effect of mTOR on 
autophagy inhibition is mediated by its inhibitory effects on Atg1 kinase 
activity in yeast and Drosophila, whereas it is not yet clear how this is carried 
out in mammalian cells (Sabatini 2006). Signals that sense nutrient deprivation, 
including hypoxia, inhibit the activity of mTOR complex 1 (mTORC1), 
composed of mTOR, RAPTOR, DEPTOR, MLST8 and PRAS40, causing 
autophagy induction, and allowing the cells to adapt to environmental changes 
through reduced growth and increased catabolism. Negative regulators of 
mTOR are the TSC1 and TSC2 tumour suppressor proteins that inhibits Rheb, 
a small GTPase required for mTOR activity (Shaw 2009). TSC1 and TSC2 are 
activated by the adenosine 5′-monophosphate (AMP)-activated protein kinase 
(AMPK), in response to low ATP concentration, or by the reduction of AKT 
activity, in response to decreased growth factor receptor signaling (Shaw 
2009).  
The Ras/cAMP-dependent protein kinase A (PKA) signaling pathway 
plays an important role in glucose sensing and down-regulates autophagy in 
parallel with the mTOR pathway acting on Atg1, which is a phosphorylation 
substrate of PKA (Budovskaya et al. 2005).  
In addition to nutrient deprivation, other cellular stress factors, that are 
often correlated each other, such as ER stress, hypoxia, oxidative stress and 
pathogen infection, are able to activate specific signaling pathways that 
regulate autophagy. In particular, since hypoxia induces ER stress through the 
unfolded protein response, and reduced mitochondrial function, the induction 
of autophagy in this condition may allow the cell to eliminate portions of 
compacted ER, preventing wasteful ATP consumption, and to reduce 
mitochondrial mass, limiting production of reactive oxygen species (He and 
Klionsky 2009). Increased autophagy would also allow the cell to generate 
ATP from catabolism at a time when ATP production by oxidative 
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phosphorylation is limited. A key mediator of the hypoxia-induced autophagy 
activation is the hypoxia-inducible factor 1 (HIF-1) that regulates the 
expression of BNIP3 and BNIP3L, two autophagy regulators of the Bcl-2 
superfamily (Zhang and Ney 2009).  
Autophagy is known to induce cell cycle arrest and has been linked to 
proliferative senescence. This effect may be largely driven by nutrient 
deprivation-induced inhibition of mTOR activity and downstream effects on 
translation of key cell cycle genes, such as cyclin D1 (Liu et al. 2006), but it is 
not clear whether autophagy can induce cell cycle arrest also independently of 
mTOR signaling.  
 
Figure 1.6 Schematic representation of mTOR pathway and its cross-talk with PI3K-
AKT (PKB) and AMPK pathways (image from Dann et al. 2007). 
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1.2.2 Autophagy and cancer 
De-regulation of the autophagic process is emerging to be an important 
etiopathological factor in several diseases, and modulation of autophagy may 
represent a promising therapeutic approach for neurodegenerative diseases and 
cancer. In the case of neurodegenerative diseases, defective autophagy seems 
to promote neurodegeneration. In fact, intracellular aggregate accumulation 
plays a particularly significant role in the aetiology of neurodegenerative 
diseases, including Alzheimer's, Huntington's and Parkinson's diseases, in 
which aggregates respectively of Tau, α-synuclein and Huntingtin are 
dependent on autophagy for their clearance from neurons (Yue et al. 2009). By 
contrast, in the case of cancer, the role of autophagy is more complex. During 
neoplastic transformation and tumour progression, autophagy may represent 
both an oncogenic and a tumour-suppressive factor. 
 
1.2.3 Tumor-suppressive functions of autophagy 
The first connection between autophagy and cancer was due to the 
observation that the essential autophagy gene ATG6/BECN1 seemed to be a 
tumour-suppressor. In fact, it is monoallelically lost in 40% to 75% of human 
prostate, breast, and ovarian cancers (Liang et al. 1999, Choi et al. 2013) and 
Becn1 heterozygous mutant mice are prone to develop liver and lung tumors 
and lymphomas (Qu et al. 2003). Nowadays, the tumor suppressive functions 
of autophagy have been extensively investigated, and include: inhibition of 
necrosis and inflammation, contribution to tumor cell death, prevention of 
oxidative stress and genomic instability, and modulation of the anti-tumor 
immune response (Janji et al. 2013).  
Since it is known that the inflammatory microenvironment plays a 
major role in tumor development, it is of note that activation of autophagy in 
tumor cells can inhibit the two forms of necrotic cell death necroptosis and 
poly-(ADP-ribose) polymerase (PARP)-mediated cell death that would, in turn, 
stimulate a robust inflammatory response (Shen and Codogno 2012). 
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Moreover, accumulation of p62/SQSTM1 in autophagy-deficient cells 
activates the pro-inflammatory transcription factor NF-κB and the stress-
responsive transcription factor NRF2, thus favoring inflammation and tissue 
injury (Levine et al. 2011).  
Consistently, autophagy-deficient tumors display an increased level of 
necrosis and inflammation. The anti-inflammatory effect of autophagy, 
together with its ability to negatively modulate epithelial-mesenchimal 
transition (EMT), plays also an anti-metastatic role (Lv et al. 2012).  
Interestingly, autophagic cell death (or type II programmed cell death), 
induced by sustained autophagy, significantly contributes to tumour cell death, 
in particular when cancer cells have acquired resistance to apoptosis, and has 
been proposed as a possible tumor suppression mechanism (Kroemer and 
Levine 2008).  
Moreover, autophagy helps normal cells to overcome several types of 
stress (e.g. metabolic, oncogenic) limiting their oncogenic potential. For 
example, autophagy can be activated in response to ER stress preventing the 
accumulation of ER chaperones, allows mitochondrial turnover avoiding 
accumulation of damaged mitochondria and reducing the risk of oxidative 
stress, and favors the degradation of damaged proteins involved in DNA 
replication, mitosis or repair preventing the accumulation of DNA damage and 
mutations. Autophagy is also able to mitigate the accumulation of genomic 
alteration by inducing mitotic senescence and limiting the proliferation of 
abnormal cells (Janji et al. 2013).  
Finally, autophagy can favour the anti-tumor immune response, 
allowing the survival of immune cells in the hypoxic tumor microenvironment, 
and potentiating immune functions, such as antigen presentation and T-cell-
mediated killing of tumor cells (Janji et al. 2013).  
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1.2.4 Oncogenic functions of autophagy 
The ambivalence of autophagy in cancer is exemplified by the 
observation that liver-specific knock-out of essential autophagy genes Atg5 or 
Atg7 produces only benign liver tumors in mice, suggesting that autophagy 
may be important in liver to suppress tumor initiation, but also that autophagy 
may be required for progression from benign to malignant disease (Takamura 
et al. 2011).  
In particular, autophagy may be oncogenic during the first steps of 
tumorigenesis, allowing cancer cells to survive under a variety of stresses and 
to cope the increased metabolic and biosynthetic demands imposed by 
deregulated proliferation. Before the beginning of neoangiogenesis, autophagy 
favors cancer cells survival in hypoxic and nutrient starvation conditions 
(White 2015).  
 
1.2.5 ULK genes 
The Unc-51-like kinase 1 (ULK1) and -2 (ULK2) are two mammalian 
homologs of the S. cerevisiase Atg1 gene, whose name derives from the C. 
elegans hortologue Unc-51. These genes encode two high molecular weight 
Ser/Thr kinases, ULK1 and ULK2, crucial for autophagy initiation. In the 
absence of pro-autophagic stimuli, mTOR interacts with, phosphorylates, and 
inactivates ULK proteins. During starvation, or in the presence of other pro-
autophagic stimuli, ULK1 and ULK2 are activated, undergo auto-
phosphorylation and phosphorylate Atg13 and FIP200 (the homolog of yeast 
Atg17). ULKs, Atg13 and FIP200 form a molecular complex that localizes at 
the phagophore and is essential for autophagy initiation (Jung et al. 2009). The 
ULKs activity is regulated by a complex interplay between AMPK and 
mTORC1. In fact, AMPK directly phosphorylates both ULK1 and ULK2, 
positively regulating their kinase activity. mTORC1, in addition to inhibit 
ULKs activity, negatively regulates the interaction between AMPK and 
ULK1/2. Moreover, ULK1 and ULK2 are able to phosphorylate and negatively 
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regulate both their positive and negative regulators, AMPK and mTORC1 
(Alers et al. 2012).  
ULK1 and ULK2 are closely related, sharing 78% homology within 
their protein kinase domains, and seem to be functionally redundant. However, 
each ULK protein has a specific role in some particular cellular contexts. For 
example, ULK1, but not ULK2, is critical to induce the autophagic response of 
cerebellar granule neurons (CGN) to low potassium concentration, and has a 
cytoprotective function in neurons (Lee and Tournier 2011). Interestingly, 
ULK2 is essential for adipogenesis and for the regulation of adipocyte lipid 
metabolism, whereas ULK1 was dispensable for this processes (Ro et al. 
2013).  
Ulk1 knock-out mice display alterations in the autophagic clearance of 
mitochondria and ribosomes during reticulocyte maturation (Kundu et al. 
2008), whereas Ulk1 and Ulk2 double knock-out induces severe defects of 
autophagy in the lung, causing pups death within 24 hours of birth for 
respiratory distress (Cheong et al. 2014).  
As autophagy in general, ULK genes seem to have a variable role in 
cancer cells, that strongly depends on cellular context and stage of 
tumourigenesis. For instance, ULK genes are tumour-suppressive in glioma 
cells: in fact, ULK2 epigenetic silencing is essential for astrocytes 
transformation, and both ULK1 and ULK2 are down-regulated in all grades of 
glioma (Shukla et al. 2014). On the other hand, hypoxia-induced ULK1 
activation sustains the survival of MCF7 and A431 cancer cell lines (Pike et al. 
2013).  
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Figure 1.7 Schematic representation of autophagosome formation. Autophagosome 
formation can be initiated via mTOR inhibition or AMPK activation. This results in the 
activating phosphorylation of ULK1 and of its complex, composed of ULK1, ULK2, Atg13, 
FIP200 and Atg101. ULK1 also phosphorylates AMBRA, a component of the PI3K CIII 
complex I (Vps34, Vps15, Atg14, and beclin-1), enabling it to relocate from the cytoskeleton 
to the isolation membrane. Phosphatidylinositol 3-phosphate (PI3P), generated by Vps34 
activity, specifically binds the PI3P effectors WD repeat domain phosphoinositide-interacting 
1 (WIPI1) and WIPI2 and catalyzes the first of two types of ubiquitination-like reactions that 
regulate isolation membrane elongation. In this first reaction, Atg5 and Atg12 are conjugated 
to each other in the presence of Atg7 and Atg10. Attachment of the fully formed complex 
containing Atg5, Atg12 and Atg16L on the isolation membrane induces the second complex to 
covalently conjugate phosphatidylethanolamine to LC3, which facilitates closure of the 
isolation membrane (image from Nixon 2013). 
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2. Aims of the study 
The above exposed considerations point out the importance of 
autophagy in cancer initiation and progression, but the mechanisms by which 
autophagy is deregulated in cancer cells are almost still unknown. Moreover, 
mutations in autophagy-related genes are rarely found in human cancers 
(White 2015), suggesting that they may not explain autophagy impairment in 
cancer cells. For this reason, investigation of transcriptional regulation and 
deregulation of autophagy-related genes appears a promising field of research 
to address this question. Considering that HMGA1 impacts on several 
biological processes by transcriptionally deregulating the expression of a lot of 
different target genes, and that overexpression of HMGA1 and impairment of 
autophagy are both common features of cancer cells, often acquired during 
cancer progression, we aimed to investigate whether there is a relationship 
between HMGA1 and autophagy in cancer cells. This hypothesis is supported 
by the evidence that HMGA1 has already been associated to some pathways 
(such as PI3K/AKT pathway) and biological processes (such as cellular 
proliferation, apoptosis, DNA repair and genomic instability) related to 
autophagy, and by some observations obtained studying the role of HMGA1 in 
skin cancer cells (described in the Results section). Therefore, we planned to 
evaluate the effects of HMGA1 knock-down on autophagy-regulating 
pathways and on autophagic flux in skin cancer cells SCC-13 and in other cell 
lines, and to identify new HMGA1-target genes that might account for the 
possible effect of HMGA1 on autophagy regulation which could represent a 
new mechanism by which HMGA1 exerts its oncogenic activity.  
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3. Materials and Methods 
Cell cultures  
HeLa cells were grown in RPMI supplemented with 10% FBS, L-
glutamine, and antibiotics (Invitrogen, Carlsbad, CA). Human epidermal 
squamous carcinoma SCC-13 cell line was kindly provided by JG Rheinwald. 
Cells were cultured in keratinocyte serum-free medium (KSFM, Invitrogen) 
with 25 mg/mL bovine pituitary extract, penicillin, streptomycin, 0.2 ng/mL 
epidermal growth factor (EGF), and CaCl2 to a final Ca2+ concentration of 0.4 
mM. To maintain healthy confluent cultures, after cultures reached 40% 
confluence, they were refed daily with 1:1 medium (1:1 vol/vol Ca2+-free 
DMEM/KSFM, supplemented as above described). HEK293 cells were 
cultured in DMEM with 10% FBS, L-glutamine, and antibiotics (Invitrogen, 
Carlsbad, CA). MEFs were cultured in DMEM with 10% FBS, L-glutamine, 
and antibiotics (Invitrogen, Carlsbad, CA). MEFs have been isolated from 12.5 
d.p.c. embryos. After head removing, embryos have been washed with PBS, 
incubated in trypsin 1% (Sigma) for 10 minutes at RT, pelletted and then 
resuspended in DMEM. MEFs have been genotyped for HMGA1 by PCR 
analysis with the following primers: 
HMGA1-Fw 5’-AGAGACAAGAATGGGAGAGC-3’ 
HMGA1wt-Re 5’-TGTTACTAGGACCCTCATGG-3’ 
HMGA1KO-Re 5’-TAAAGCGACTGCTCCAGACT-3’ 
The wild-type allele is amplified using HMGA1-Fw + HMGA1wt-Re primers, 
whereas the knock-out allele is amplified using HMGA1-Fw + HMGA1KO-Re 
primers. 
 
Transfections and plasmids 
Cells were transfected with plasmids by Lipofectamine plus reagent 
(Invitrogen) according to the manufacturer’s instructions. Cells were 
transiently transfected with pcDNA3.1-Hmga1b (Pierantoni et al. 2003). 
Luciferase activity was analyzed by LightSwitch Luciferase Assay kit (Switch 
! 34!
Gear Genomics), according to manufacturer’s instructions. ULK1-luc (cod. 
SKU:S707592) and ULK2-luc (cod. SKU:S709931) plasmids were from 
Switch Gear Genomics.  
 
RNA interference, RNA extraction and quantitative Real-Time PCR 
(qRT-PCR) 
RNA interference was obtained by specific siRNAs for HMGA1 
[QiagenHs_HMGA1_5 (SI02662023) Sense strand and 
GGACAAGGCUAACAUCCCATT Antisense strand 
UGGGAUGUUAGCCUUGUCCAG] or ULK1 (LifeTechnologies, Cat. # 
AM51331) using Lipofectamine RNAiMAX (Invitrogen) according to 
manufacturer’s instructions. As negative control, Qiagen AllStars control 
siRNA (SI03650318) was used. Total RNA was isolated using TRI-reagent 
solution (Sigma, St Louis, MO, USA) and treated with DNase (Invitrogen). 
Reverse transcription was performed according to standard procedures 
(Qiagen, Valencia, CA).  qRT-PCR analysis was performed using the Power 
SYBR Green PCR Master Mix (Applied Biosystems) with following primer 
sequences:  
humanHMGA1-Fw 5’-CAACTCCAGGAAGGAAACCA-3’ 
humanHMGA1-Re 5’-AGGACTCCTGCGAGATGC-3’ 
humanULK1-Fw 5’-CAGACAGCCTGATGTGCAGT-3’ 
humanULK1-Re 5’-CAGGGTGGGGATGGAGAT-3’  
humanULK2-Fw 5’-TTTAAATACAGAACGACCAATGGA-3’ 
humanULK2-Re 5’-GGAGGTGCCAGAACACCA-3’ 
humanACTB-Fw 5’-CCAACCGCGAGAAGATGA-3’         
humanACTB-Re 5’-CCAGAGGCGTACAGGGATAG-3’ 
mouseUlk1-Fw 5’-GGATCCATGGTGTCACTGC-3’ 
mouseUlk1-Re 5’-CAAGGGCAGCTGATTGTACC-3’ 
mouseUlk2-Fw 5’-CACCATCTTGTCGCTTTGC-3’ 
mouseUlk2-Re 5’-GGATAAGTTTTCTTCCTGAATATGCT-3’ 
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mouseActb-Fw 5’-CTAAGGCCAACCGTGAAAAG-3’         
mouseActb-Re 5’-ACCAGAGGCATACAGGGACA-3’ 
 
Growth curve and cell viability assay 
SCC-13 cells were seeded in six-well plates, interfered and transfected 
as above described. Ctli and HMGA1i cells were counted after 48, 72 and 96 h.  
Cell viability of cells was quantified by MTS (3-(4,5 dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl-2-(4-sulfophenyl)-2H-tetrazolium) assay 
(Promega's CellTiter® 96 AQueous One Solution, Promega Fitchburg, WI, 
USA). Cells were seeded in 96-well plates at 5x103 cells per well, then 
interfered and transfected as above described. After 72 h, absorbance was 
measured at 490 nm.  
 
Western blotting and antibodies 
Antibodies directed against HMGA1 proteins were already described 
(Pierantoni et al. 2003b). Commercial antibodies were: anti-pSer473-AKT 
(#9271), anti-AKT (#9272), anti-caspase 8 (1C-12), anti-caspase 7, anti-
LC3A/B, anti-PARP (46D11) and anti-ULK1 (R600) antibodies from Cell 
Signaling Technology, MA, USA; anti-actin (I19), anti-p21(C-19), anti-
phospho S6 ribosomal protein (Ser240/244), anti cyclin D1 A12 (sc8396) and 
anti cyclin E E20 (sc481) were from Santa Cruz Biotechnology, Santa Cruz; 
anti-p27 (610241) and anti-p62/SQSTM1 (610833) were from BD Biosciences 
(Franklin Lakes, NJ USA); anti-GAPDH was from ABM Materials 
(Richmond, BC, Canada). ECL System was purchased from Amersham 
Pharmacia (Buckinghamshire, UK).  
 
Chromatin Immunoprecipitation (ChIP) Assay 
After transfection, cells have been treated with formaldehyde 1%, 
washed and then lysed isolating the nuclei. Then the nuclei have been in turn 
lysed and chromatin has been sonicated. Then, samples have been processed 
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and immunoprecipitated using anti-HMGA1 antibody or normal rabbit IgG as 
negative control. For PCR analysis, 2µl out of 150µl immunoprecipitated DNA 
was used with primers described below. GAPDH promoter amplicon was used 
as negative control in all the experiments. Input DNA was used as positive 
control.  
Primers used were:  
ULK1-prom-Fw 5’-TGCCCTGTTCCATATTTTGC-3’   
ULK1-prom-Re 5’-ACCCAAACCAACGACATAGC-3’   
ULK2-prom-Fw 5’-AGCTGGGGATGGAGAGTACC-3’   
ULK2-prom-Re 5’-AGAGACCGGAGCGGAAACT-3’   
GAPDH-prom-Fw 5’-CCCAAAGTCCTCCTGTTTCA-3’   
GAPDH-prom-Re 5’-GTCTTGAGGCCTGAGCTACG-3’   
 
Fluorescence Microscopy 
Lysotracker Probe (Molecular Probes) and monodansylcadaverin 
(MDC, 50 µM, Sigma) were used to label lysosomes and autophagosomes, 
respectively. Briefly, cells grown on coverslips were incubated with 
Lysotracker Probe for 1h at 37°C before fixation (4% PFA). Cells grown on 
bottom-glass dishes were incubated with MDC in PBS for 10 min at 37°C and 
imaged in vivo in PBS.  
 Cells stained with LC3 antibody (nanoTools) were fixed with methanol, 
quenched with 0.2% BSA/10% FBS in PBS for 30 min and permeabilized with 
0.2% TX-100 for 7 min. Primary antibodies were detected with TRITC-
conjugate secondary antibodies (Jackson ImmunoResearch Laboratories, Inc). 
Images were collected using a laser scanning microscope (LSM 510 META, 
Carl Zeiss Microimaging, Inc.) equipped with a Plan Apo 63x oil-immersion 
(NA 1.4) objective lens.  
 Quantification and morphometric analyses were carried out by using 
LSM 510 software. The mean ﬂuorescence intensities in selected regions of 
interest of equal size were measured. For the quantification we acquired the 
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images, for each fluorophore, with the same setting (laser power, detector gain) 
as well as we kept the same threshold of fluorescence intensity in all 
experimental conditions (control and silenced cells). We evaluated the size of 
phagosome or lysosome compartments measuring the area occupied from each 
organelle marker that takes in account both the number and the dimension of 
these compartments.  
 
Statistical analysis 
Student’s t-test was used to determine the significance for all the 
quantitative experiments. Error bars represent the standard deviation (SD) of 
the average.  
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4. Results 
4.1 Knock-down of HMGA1 induces autophagy in skin cancer 
cells. 
Skin cancer is the most frequently occurring among all types of human 
cancer, and cutaneous squamous cell carcinoma (CSCC), sometimes referred to 
as "epidermoid carcinoma" and "squamous-cell epithelioma", is the second 
most common of all the skin tumors, representing about 20% of non-melanoma 
skin cancers (NMSCs) (Uribe and Gonzalez 2011). Skin color, sunlight 
exposure and immunosuppression are risk factors for CSCC, with chronic sun 
exposure being the strongest environmental risk factor. CSCC is a serious 
health concern in Caucasian, displaying a mortality rate comparable to that of 
melanoma (Karia et al. 2012). In fact, similarly to melanoma, CSCC is more 
aggressive than other skin carcinomas, as 12% of cases metastasize and 1.5% 
of patients will succumb to this disease. The rising incidence and morbidity 
rates of CSCC have generated great research interest, in particular with regard 
to the progression and metastatization of this type of cancer (Sun et al. 2016). 
CSCC is a cancer of the squamous cells, the cells that compose all the different 
layers of the epidermis of the skin, with the exception of the basal layer. 
However, SCC can occur also in other squamous epithelia, such as those of 
lips, mouth, esophagus, urinary bladder, prostate, lung, vagina, and cervix. The 
SCCs of different body sites are highly heterogeneous, and can consistently 
differ in their symptoms, natural history, prognosis, and response to treatment. 
The functional role and the oncogenic activity of HMGA1 has been 
extensively described in several types of cancer cells (Fusco and Fedele 2007), 
but it has not been investigated in skin cancer cells so far. To this aim, we 
focused our attention on CSCC, and selected as experimental model the human 
squamous carcinoma cell line SCC-13, established by Rheinwald and Beckett 
in 1981.  
To evaluate the effects of the lack of HMGA1 in SCC-13 cells, we 
knocked-down its expression using an RNA-interference (RNAi) approach. In 
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particular, HMGA1 was silenced by transfecting short interfering RNAs 
(siRNAs) that target its mRNAs. As shown in figures 4.1A-B, a drastic 
reduction in HMGA1 expression was observed in the HMGA1-interfered cells 
(HMGA1i), at both mRNA and protein level. Then, we investigated whether 
HMGA1-interference affects cell proliferation, viability and apoptosis in SCC-
13 cells, as described in other cell types. In particular, to compare the 
proliferation rate of control cells tranfected with a scrambled siRNA (Ctli), and 
HMGA1i cells, we performed a growth curve assay. As shown in figure 4.1C, 
a strong reduction in the number of HMGA1i with respect to Ctli cells was 
observed after 48, 72 and 96 hours post inhibition of HMGA1 expression. 
Interestingly, between 72 and 96 hours post-transfection, the number of Ctli 
cells continued to increase, whereas that of HMGA1i cells decreased, 
suggesting that HMGA1-knock down (KD) affects cell survival. The evidence 
that HMGA1i have a slower proliferation rate compared to Ctli cells is 
supported by the Western blot analysis of cell cycle modulators. We found that 
that HMGA1i cells express higher levels of the CDK inhibitors p27 and p21 
and lower levels of cyclin D1 and cyclin E than control cells (figure 4.1D).  
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Figure 4.1 HMGA1 knock-down impairs proliferation of SCC-13 cell line. Control (Ctli) 
and HMGA1-interfered (HMGA1i) SCC-13 cells were tested for the expression of HMGA1 by 
qRT-PCR (A) and Western blotting (B). Actin was used as loading control. (C) Growth of 
HMGA1-interfered SCC-13 cells. Cells were plated as described in “Materials and Methods” 
and counted daily at 48, 72 and 96 h. (D) Proteins extracted from Ctli and HMGA1i cells were 
analyzed by Western blotting for Cyclin D1, Cyclin E, p21 and p27 protein levels. Actin was 
used as loading control.  
 
Subsequently, viability of the HMGA1i cells has been evaluated 
performing a CellTiter assay, founding that it was significantly lower (about 
40%) than that of control cells (figure 4.2A). To verify whether the reduced 
viability of HMGA1i is associated to type I programmed cell death (apoptosis), 
we analyzed PARP, caspase-7 and caspase-8 expression by Western blot. As 
shown in figure 4.2B, we observed neither a decrease in the full-length inactive 
forms of these apoptotic markers, nor an accumulation of the cleaved ones, 
deducting that HMGA1-KD is not sufficient to induce apoptosis in SCC-13 
cells in the absence of pro-apoptotic stimuli.  
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Figure 4.2 HMGA1 knock-down impairs viability of SCC-13 cell line without inducing 
apoptosis. (A) Cell viability of Ctli and HMGA1i cells was evaluated as described in 
“Materials and Methods” section. Error bars represent the mean ± S.D. of a representative 
experiment performed in triplicate. (B) The same extracts of (Fig. 4.1D) were tested by 
Western blotting with the indicated antibodies directed against proteins involved in the 
apoptotic process. Actin was used as loading control. 
 
These data indicate that HMGA1 silencing impairs proliferation and 
viability of SCC-13 cells without inducing apoptosis, so we investigated 
whether these phenomena were associated to type II programmed cell death 
(autophagic cell death). A connection between HMGA1 and autophagy 
regulation has been suggested by the previous observations that HMGA1 
overexpression is able to activate PI3-K/AKT cascade (Liau et al. 2007), a 
major signaling pathway regulating autophagy, and mammalian Target of 
Rapamycin Complex 1 (mTORC1) (Laplante and Sabatini 2012). Thus, we 
investigated whether HMGA1-KD is able to reduce the activation of AKT and 
of ribosomal protein S6, the final read-out of the mTOR pathway in SCC-13 
cell line. Phosphorylation of AKT Ser473 and S6 Ser240/244 is reduced in 
HMGA1i with respect to Ctli cells, as shown in (figure 4.3A), suggesting that 
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the KD of HMGA1 expression may trigger traits of autophagy in skin cancer 
cells. Subsequently, to verify whether depletion of HMGA1 really affects the 
autophagic flux, we evaluated microtubule-associated protein light chain 3 
(LC3) processing and degradation by Western blot analysis. The conversion-
rate from LC3-I to LC3-II form is suggestive of autophagosomes assembly, 
since LC3-I>LC3-II conversion is due to the proteolysis and PE-conjugation of 
LC3-I that occurs during autophagosomes formation. On the other hand, since 
LC3-II itself is degraded inside autolysosomes during autophagy, LC3-II 
degradation rate indicates the intensity of the autophacic flux. For these 
reasons, when the autophagic flux is active, both LC3-I and LC3-II may 
decrease. Therefore, to better estimate the autophagic flux, it is appropriate to 
evaluate the LC3-II/LC3-I ratio in the presence and in the absence of lysosome 
inhibitors, which allow LC3-II to accumulate on the autophagosome membrane 
(Mizushima and Yoshimori 2007).  
On these bases, to inhibit lysosomes, Ctli and HMGA1i cells were 
treated for 16 hours with NH4Cl and leupeptin, at a concentration respectively 
of 20 mM and 100 µM, as previously described (Vitale et al. 2013). The ratio 
between LC3-II and LC3-I forms was increased in HMGA1i in comparison 
with the control cells in the presence of lysosomes inhibitors, whereas, in their 
absence, LC3-II was almost all degraded, and LC3-I was less abundant in 
HMGA1i than in Ctli cells.  
The consistent degradation rate of LC3-II, observed in the absence of 
lysosomes inhibitors, indicates that both Ctli and HMGA1i SCC13 cells 
display high levels of autophagy. On the other hand, the increased LC3-II/LC3-
I ratio in the presence of NH4Cl and leupeptin, and the decreased levels of 
LC3-I in HMGA1i cells indicate that autophagosomes assembly and 
autophagolysosomes activity increase after HMGA1-KD (figure 4.3B).  
Consistently, the HMGA1-knockdown increased also the degradation of 
p62/SQSTM1, another protein that, as LC3, is recruited and degraded in the 
autophagolysosomes, representing an indicator of the autophagic flux (figure 
! 43!
4.3C). In fact, in the absence of lysosome inhibitors, p62/SQSTM1 levels were 
lower in HMGA1i than in Ctli cells, whereas the blockage of 
autophagolysosomes activity revealed a higher accumulation of this protein in 
the HMGA1-depleted cells.  
 
 
 
Figure 4.3 HMGA1 depletion induces autophagy. (A) Immunoblot detection of p-AKT 
(Ser473), total AKT and p-S6 expression levels in Ctli and HMGA1i cells. Actin was used as 
loading control. (B-C) Proteins extracted from Ctli and HMGA1i cells untreated or treated with 
20 mM NH4Cl and 100 µM leupeptin for 16 h were tested for LC3-I>II conversion levels (B) 
and for p62/SQSMT1 expression (C) by Western blotting. Actin was used as loading control.  
 
 
The above described biochemical data indicate that HMGA1-KD 
induces down-regulation of AKT and mTOR pathways, associated to increased 
autophagic flux in SCC-13 cells. To confirm and support these data with 
another approach, we assessed the distribution of some markers of autophagy 
by confocal fluorescence microscopy. First of all, we evaluated the number and 
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size of autophagosomes, stained them in vivo using the ﬂuorescent dye 
monodansylcadaverine (MDC). Autophagosomes of HMGA1i cells were more 
and surprisingly bigger than those of Ctli cells, to the point that the area 
occupied by MDC-positive structures were consistently higher in the HMGA1-
depleted cells. Then, we evaluated the subcellular distribution of LC3 and 
p62/SQSTM1. The proportion of these proteins that has not been recruited to 
the autophagosomes gives a diffuse cytoplasmic staining, whereas the LC3- or 
p62/SQSTM1-positive dots (or puncta) represent autophagosomes or 
autophagolysosomes in which these proteins have been recruited. In agreement 
with Western blot analysis, both LC3 and p62/SQSTM1 were strongly 
recruited in autophagosome compartment in HMGA1i cells (figure 4.4A, 
middle panels), as demonstrated by the increase of LC3- and p62/SQSTM1 -
positive puncta. Finally, we found that the depletion of HMGA1 caused also an 
increase in number and size of lysosomes, labelled with the lysostracker dye 
(figure 4.4A, upper panels). Interestingly, in HMGA1i cells there was a drastic 
expansion (3/4-fold increase) of the area occupied also by LC3 puncta and 
lysosomes (figure 4.4B). 
Taken together, these data support the idea that the depletion of 
HMGA1 increases the activation of the autophagic pathway in SCC-13 cells.  
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Figure 4.4 Evaluation of autophagic markers in HMGA1i-SCC-13 cells by 
immunofluorescence. (A) Ctli and HMGA1i cells were stained with monodansylcadaverin 
(upper panels, MDC, in green), LC3 specific antibody (middle panels, in red), p62/SQSTM1 
specific antibody (middle panels, in green), or lysotracker (lower panels, in red) as described in 
“Materials and Methods”. Serial confocal sections were collected. Bars, 11 µm. For each 
condition, image magnification was shown in the squares at right. Bars, 6 µm. Mean 
fluorescence intensity (arbitrary unit, a.u.) for each marker in Ctli and HMGA1i cells is shown. 
Experiments were performed at least two independent times (n ≥50 cells). Error bars, means ± 
SD; * p < 0.0001. (B) The area occupied by each organelle marker was measured in Ctli and 
HMGA1i cells. Experiments were performed at least two independent times (n ≥50 cells). 
Error bars, means ± SD; * p < 0.0005.  
! 46!
4.2 HMGA1 regulates autophagy not only in skin cancer cells.  
Since HMGA1 is an architectural transcription factor that activates, 
recruits to or displaces from specific promoters other transcriptional regulators, 
its activity strongly depends on the set of proteins expressed by a particular cell 
type, thus its effects may vary on the basis of the cellular context. In order to 
verify whether the autophagy increase induced by the KD of HMGA1 
expression is not restricted to skin cancer cells, we analyzed the effect of 
HMGA1 silencing on autophagic markers also in HeLa cervix cancer cells, a 
very common model of cancer cells in culture. As observed in SCC-13 cells, 
depletion of HMGA1 induces autophagy also in HeLa cells, as demonstrated 
by both Western blot analysis and confocal fluorescence microscopy 
experiments. In fact, phospho-S6 levels were lower in HMGA1-depleted cells 
with respect to the control cells (figure 4.5B), and LC3-I>II conversion levels 
and p62/SQSTM1 degradation were higher in proteins extracted from 
HMGA1i-HeLa cells untreated or treated with 20 mM NH4Cl and 100 µM 
Leupeptin for 16 hours in comparison with the control transfected cells (figure 
4.5C). Consistently, microscopy analysis of MDC, LC3, p62/SQSTM1 and 
lysotracker stainings confirmed these data (figure 4.6).  
 
Figure 4.5 HMGA1 depletion induces autophagy also in HeLa cells. (B) Immunoblot 
detection of HMGA1 and (C) p-S6 expression levels in Ctli and HMGA1i cells. Actin was 
used as normalization. (D) Proteins extracted from Ctli and HMGA1i cells, untreated or treated 
with 20 mM NH4Cl and 100 µM leupeptin for 16 h, were tested for LC3-I>II conversion and 
p62/SQSMT1 expression levels by Western blotting. Actin was used as loading control. 
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Figure 4.6 Evaluation of autophagic markers in HMGA1i-HeLa cells by 
immunofluorescence. Ctli and HMGA1i cells were stained with monodansylcadaverin (upper 
panels, MDC, in green), LC3 specific antibody (middle panels, in red), p62/SQSTM1 specific 
antibody (middle panels, in green), or lysotracker (lower panels, in red). Serial confocal 
sections were collected. Bars, 11 µm. Mean fluorescence intensity (arbitrary unit, a.u.) for each 
marker in Ctli and HMGA1i cells is shown. Experiments were performed two independent 
times (n ≥ 50 cells). Error bars, means ± SD; * p < e-7 for MDC and lysotracker; p < 0.01 for 
LC3.  
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Moreover, we evaluated the autophagic flux also in wild-type (WT) 
MEFs, that physiologically express the HMGA1 proteins, and in their Hmga1 
null (KO) counterpart. Interestingly, confocal microscopy showed that KO 
MEFs did not display an appreciable enlargement of autophagosome-lysosome 
compartment with respect to their WT counterpart (figure 4.7A), but the 
treatment with several autophagy-inducers revealed that Hmga1-/- MEFs are 
more susceptible to autophagy in comparison with WT ones (figure 4.7B). In 
fact, after 6 hours of starvation in HBSS or after treatment with 1 µM of the 
mTOR-inhibitor rapamycin, LC3-I>II conversion was higher in KO MEFs 
with respect to WT. 
These data clearly indicate that the involvement of HMGA1 proteins in 
the process of autophagy is not restricted to cancer cells, although it may 
depend on cellular context.  
Figure 4.7 Hmga1 genetic ablation induces autophagy in MEFs (A) Hmga1 WT and KO 
MEFs were stained with monodansylcadaverin (upper panels, MDC, in green) or lysotracker 
(lower panels, in red). Bars, 11 µm. (B) Proteins extracted from WT and KO MEFs untreated 
or treated with HBSS (for 6 h) or rapamycin (for 16 H) in presence or absence of 20 mM 
NH4Cl and 100 µM leupeptin for 16 h were tested for LC3-I>II conversion levels by Western 
blotting. Actin was used as loading control. 
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4.3 HMGA1 negatively regulates the expression of ULK1 and 
ULK2. 
Even though HMGA1 has some “extra-nuclear” functions, such as!regulation!of!mitochondrial function and mitochondrial DNA repair efficiency 
(Mao et al. 2009), the vast majority of its effects are due to the transcriptional 
regulation of specific target genes. To understand which are the HMGA1-
regulated genes by which HMGA1 could regulate autophagy, we looked for 
autophagy-related genes in the data set of a microarray analysis that we had 
performed to compare the transcriptome of Hmga1 KO and WT MEFs 
(unpublished data). Applying biostatistical analysis, we found several 
autophagy-related transcripts differentially expressed in KO compared to WT 
MEFs with a fold-change > 2 (data not shown). We focused our attention on 
the most upregulated gene in KO MEFs, that was Unc-51-like kinase 2 (Ulk2), 
whose gene product, the Ser/Thr kinase ULK2, is a recognized master 
regulator of autophagy, belonging to the autophagy-initiating complex 
(Mizushima 2010). Subsequently, the upregulation of Ulk2 in Hmga1 KO 
MEFs was confirmed by qRT-PCR, and we analyzed also the expression of its 
closely related paralogue Ulk1, founding that it is moderately overexpressed in 
KO vs WT MEFs (fold-change ≈1,9) (figure 4.8A).  
To test whether HMGA1-KD induces ULK genes de-regulation also in 
human cancer cells, we analyzed by qRT-PCR the expression of ULK1 and 
ULK2 in HMGA1-depleted HeLa and SCC-13 cell lines. As shown in figure 
4.8A, both ULK1 and ULK2 were upregulated following HMGA1 depletion. 
Interestingly, in both HeLa and SCC-13 cells, the fold change of ULK1 (≈3-4) 
was higher than that of ULK2 (≈2,5). In addition, we confirmed the 
upregulation of ULK1 also at protein level by Western blotting analysis (figure 
4.8B).  
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Figure 4.8 Hmga1 modulates ULK1 and ULK2 mRNA expression levels in several cells. 
(A) RNA extracted from control (Ctli) or HMGA1-interfered (HMGA1i) SCC-13 or HeLa 
cells and from WT and KO MEFs, were analyzed by qRT-PCR for ULK1 and ULK2 
expression. The actin expression level has been used for data normalization. Data are mean ± 
SD of a representative experiment performed in triplicate. (B) Proteins extracted from control 
and HMGA1i SCC-13 and HeLa cells were tested for ULK1 expression by western blotting 
experiment. Vinculin was used as loading control. 
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To verify whether ULK1 and ULK2 may be direct targets of HMGA1, 
we tested whether ULK1 and ULK2 promoter regions are bound by HMGA1. 
To this aim we identified putative AT-rich HMGA1 binding sites in the 
promoter regions of these genes, using bioinformatic methods (PROMO 3.0). 
Then we verify the binding of HMGA1 to these AT-rich regions of the ULK 
promoters by chromatin immunoprecipitation (ChIP) assays in HeLa cells. 
Thus, DNA-chromatin complexes were subjected to immunoprecipitation with 
anti-HMGA1 or aspecific rabbit polyclonal IgGs as negative control. The 
recovered DNA was subsequently analyzed by qRT-PCR, using primers 
spanning -878/-713 region of the ULK1 promoter and +129/+352 region of the 
ULK2 promoter. As shown in figure 4.9A, occupancy of ULK1 and ULK2 
promoters by HMGA1 has been detected in the anti-HMGA1-precipitated 
chromatin from HeLa cells, whereas no amplification was observed in samples 
immunoprecipitated with rabbit IgGs. As negative control, the 
immunoprecipitated DNA has been amplified using primers for the 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene promoter.  
Finally, to evaluate the ability of HMGA1 to regulate the transcriptional 
activity of ULK1 and ULK2 promoters, we performed luciferase activity assays 
in HeLa cells. To this aim, Ctli and HMGA1i HeLa cells have been transfected 
with a reporter vector carrying the luciferase gene under the control of the 
ULK1 or ULK2 promoter. As shown in figure 4.9B, HMGA1 depletion 
increased the transcriptional activity of both ULK1 and ULK2 promoters. To 
further verify the ability of HMGA1 to regulate the activity of Ulk1 promoter, 
we used HEK293 cells that represent a useful system to study the effects of 
both depletion and overexpression of HMGA1 protein. Accordingly, depletion 
of HMGA1 protein increased ULK1 promoter activity also in these cells, 
whereas HMGA1 overexpression significantly reduced it (figure 4.9C). All 
these data strongly support a critical role of HMGA1 in the negative regulation 
of ULK1 and ULK2 gene expression exerted by binding ULK1 and ULK2 
promoters and thereby decreasing their transcriptional activity. 
! 52!
 
Figure 4.9 HMGA1 protein regulates ULK1 and ULK2 transcription. (A) ChIP was 
performed in HeLa cells. Soluble chromatin was immunoprecipitated with anti-HMGA1 
antibodies. The DNAs were amplified by qPCR using primers covering specific regions of 
human ULK1 and ULK2 promoters (-878/-713 and +129/+352, respectively). IgG were used as 
negative control of immunoprecipitation. Amplification of the immunoprecipitated DNA using 
primers for the GAPDH gene promoter was used as control of specificity. Data are mean ± SD 
of a representative experiment performed in triplicate. (B) Analysis of ULK1 and ULK2 
luciferase-reporter activity in Ctli and HMGA1i HeLa cells. All transfections were performed 
in triplicate. Data are mean ± SD of three independent experiments. The same analysis was 
performed for ULK1 promoter activity in Ctli and HMGA1i HEK293 cells (C, left panel). 
Analysis of ULK1 promoter activity was also evaluated in HEK293 cells transiently transfected 
with empty vector (CV) or 0.8 µg of pcDNA3.1-Hmga1b expression vector (C, right panel). 
All transfections were performed in triplicate. Data are mean ± SD of three independent 
experiments. 
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4.4 Knock-down of ULK1 prevents autophagy induced by 
HMGA1-depletion. 
The above described data indicate that HMGA1 is able to bind the 
promoters of ULK genes and to modulate their transcriptional activity. Since 
ULK1 and ULK2 are master regulators of autophagy, we hypothesized that the 
regulation of their expression may account for the induction of autophagy 
caused by HMGA1-KD. In particular, we focused on ULK1, which is the most 
up-regulated in response to HMGA1-depletion in both SCC-13 and HeLa cells.  
To confirm that the effects of HMGA1 depletion on autophagy were 
mediated by ULK1 upregulation, HeLa cells were interfered for both HMGA1 
and ULK1 expression (figure 4.10A) using specific siRNAs. As shown in 
figure 4.10B, we confirmed the efficacy of HMGA1 and ULK1 silencing, and 
found that ULK1 silencing drastically reduced LC3I>II conversion induced by 
HMGA1 depletion. These data suggest that the autophagy induced by 
HMGA1-depletion is, at least in part, due to ULK1 upregulation. 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 Effects of HMGA1 silencing in autophagy are mediated by Ulk1 depletion. 
(A) Proteins extracted from Ctli, HMGA1i, ULK1i and HMGA1i/ULK1i HeLa cells were 
tested for the expression of ULK1 and HMGA1 by Western blotting analysis. Actin was used 
as loading control. (B) The same samples untreated or treated with 20 mM NH4Cl and 100 µM 
leupeptin for 16 h were tested for LC3-I>II conversion levels. Actin was used as loading 
control. 
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5. Discussion 
Since HMGA proteins are overexpressed in several human 
malignancies, and their overexpression levels correlate with cancer 
progression, high aggressiveness, chemoresistance and poor prognosis (as 
reviewed in Fusco and Fedele 2007, Liau and Wang 2008), they represent 
promising prognostic markers and therapeutic targets for oncological patients. 
Plenty of studies have underlined the causal role of HMGA1 and HMGA2 in 
cancer initiation and progression, unrevealing several mechanisms by which 
HMGA proteins exert their oncogenic activity. In particular, it has been 
demonstrated that HMGA1 is able to: a) antagonize p53 function and inhibit 
p53-induced apoptosis (Frasca et al. 2006, Esposito et al. 2010); b) regulate 
cancer stem cell division (Puca et al. 2014); c) impair DNA repair machineries 
(Palmieri et al. 2011); c) transcriptionally regulate miRNAs and genes involved 
in the control of the cell cycle (Tessari et al. 2003, Mussnich et al. 2013) and 
induction of epithelial-mesenchymal transition (Reeves et al. 2001, Pegoraro et 
al. 2013); d) promote AP-1 activity (Vallone et al. 2007); e) induce 
chromosome instability (Pierantoni, Conte et al. 2015, Pierantoni, Conte et al. 
2016). Nevertheless, as HMGA1 binds DNA throughout the genome, inducing 
massive chromatin remodeling and considerable changes in gene expression, it 
is general opinion that it can promote tumorigenesis also by other unidentified 
mechanisms.  
Moving from the observation that HMGA1-knock-down (KD) 
decreases proliferation and survival, without inducing apoptosis, in human 
epidermal squamous cells carcinoma SCC-13 cell line, we demonstrate that 
HMGA1 plays an important role in the regulation of autophagy, a key process 
in cancer cells survival, thus suggesting a novel mechanism of HMGA1-
mediated oncogenesis. Indeed, KD of HMGA1 increases autophagy in SCC-13 
cells, as demonstrated by the appearance of the typical autophagic features. In 
fact, HMGA1-silenced cancer cells display both a reduced phosphorylation of 
AKT and of the final read-out of the mTORC1 pathway, the ribosomal S6 
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protein, and up-regulation of autophagic flux markers, such as LC3-I>LC3-II 
conversion-rate, p62/SQSTM1 degradation, and LC3 and p62/SQSTM1 
redistribution from a diffuse pattern to cytoplasmic puncta representing 
autophagosomes or autophagolysosomes. Interestingly, the effect exerted by 
depletion of HMGA1 on autophagy is not restricted to SCC-13 cells. In fact, 
the induction of autophagy, assessed by both biochemical and morphological 
analysis, has been obtained also in HMGA1-KD cervix cancer HeLa cells. 
Morover, Hmga1-KO MEFs showed a higher susceptibility to autophagy in 
comparison to the WT counterpart, even though they do not display 
appreciable differences in the autophagosomal/lysosomal compartment under 
basal conditions. Considering that HMGA1 is an architectural transcription 
factor, whose activity strongly depends on its molecular partners and on 
cellular context, we cannot exclude that its effects on autophagy regulation 
could be different, or even absent, in other cell types. In particular, it would be 
of interest to investigate the relation between HMGA1 and autophagy also in 
non-transformed epidermal cells. 
A microarray analysis, performed in Hmga1 WT and KO MEFs, and 
confirmed by qRT-PCR, suggested that the expression of the two autophagy-
initiating Ser/Thr kinases ULK1 and ULK2 is up-regulated as a consequence of 
Hmga1 genetic ablation. On the basis of this evidence, to understand the 
mechanism underlying the increase in autophagy induced by HMGA1-
silencing, we analyzed the expression of ULK1 and ULK2 in HMGA1i-SCC-
13 and HMGA1i-HeLa cells. qRT-PCR analysis revealed that both ULK1 and 
ULK2 are upregulated with about 4- and 3-fold change, respectively, in 
HMGA1-interfered cells with respect to control cells. Then, ChIP experiments 
showed that HMGA1 protein is able to bind the promoter regions of these 
genes, and subsequently functional assays demonstrated that HMGA1 is also 
able to repress UKL1 promoter activity. These data indicate that ULK genes are 
new direct targets of HMGA1 which is able to negatively modulate their 
expression. Finally, we were able to demonstrate that the block of ULK1 
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expression significantly reduces the autophagic effects induced by HMGA1 
silencing in HeLa cells, indicating that HMGA1-driven autophagy regulation 
is, at least in part, due to ULK1 transcriptional modulation.  
It is worth of note that other studies suggested a possible functional 
relationship between HMGA1 and autophagy, and that this relation may be 
based also on other mechanisms, in addition to ULK genes regulation. Indeed, 
it has been reported that HMGA1 overexpression activates the 
phosphatidylinositol-4,5-bisphosphate-3 kinase (PI3K)/AKT signaling 
pathway, enhancing phosphorylation of AKT at serine 473 (Liau et al. 2007). 
In addition to AKT and PI3K, also BCL-2 and NF-kB are HMGA1-regulated 
oncogenic proteins that repress autophagy. In particular, BCL-2, upregulated in 
cancer cells by HMGA1 that antagonizes the p53-mediated transcriptional 
repression of the BCL2 gene, inhibits autophagy and prevents autophagic cell 
death by sequestering the essential autophagy initiator Beclin 1 (Marquez and 
Xu 2012).  
The NF-κB family of transcription factors plays a pivotal role in 
regulating inflammation and innate and adaptive immune responses. It is 
widely demonstrated that NF-κB promotes initiation and progression of certain 
cancers, because of its ability to upregulate genes involved in cell survival, 
invasion, angiogenesis, and metastasis. HMGA proteins interact with NF-κB 
and promote its activity, enhancing the binding to specific NF-κB target 
sequences (Trocoli and Djavaheri-Mergny 2011). NF-κB has a well 
characterized anti-apoptotic activity, and, recently, it is emerging a complex 
relationship between NF-κB and autophagy. In fact, on one hand, some NF-κB 
signaling components are degraded by autophagy or are regulated by 
autophagy-related proteins, and NF-κB protein is positively or negatively 
regulated by p62/SQSTM1, depending on environmental factors and cellular 
context. On the other hand, NF-κB itself regulates autophagy at several levels: 
NF-κB activates mTOR pathway and represses autophagy in Ewing's sarcoma, 
! 57!
breast, and leukemia cancer cell lines. Moreover, NF-κB directly regulates the 
transcription of some autophagy-related genes, such as BECN1 coding for 
Beclin 1 (Trocoli and Djavaheri-Mergny 2011). On these bases, we can 
speculate that the physical and functional interaction between HMGA1 and 
NF-κB may be involved in the regulation of autophagy and autophagy-related 
genes.  
More recently, it has been demonstrated that HMGA1 is able to 
positively regulate the transcription of the glucose transporter SLC2A3/GLUT3 
gene, thus increasing glucose uptake and ATP levels leading to AMPK 
inactivation with the consequent inhibition of autophagy (Ha et al. 2012).  
Furthermore, a link with autophagy has been demonstrated also for 
HMGB1, a member of another HMG subfamily, that acts as both an 
architectural chromatin-binding factor and an extracellular signaling molecule 
during inflammation, cell differentiation, cell migration, and tumor metastasis. 
Extracellular HMGB1 is released from necrotic cells and secreted by immune 
cells, whereas HMGB1 nuclear sequestration is associated with apoptotic, but 
not necrotic, cell death. Recently, it has been demonstrated that cytosolic 
HMGB1 has pro-autophagic effects. In fact, cytosolic translocation of 
HMGB1, induced by stimuli that enhance ROS, induces autophagy because 
HMGB1 binds BECLIN1 in the cytoplasm, displacing it from BCL-2 and 
allowing the formation of the class III PI3K-BECLIN1 complex (Tang et al. 
2010). It could be worth of note to investigate whether also the cytosolic 
proportion of HMGA1 is implied in autophagy regulation.  
Interestingly, the role of extra-cellular HMGB1 has recently been 
studied in SCC-13 cells, founding that it enhances cell migration in a time- and 
dose-dependent manner, and activates the PI3K/AKT and mitogen-activated 
protein kinase (MAPK) signaling pathways. These data suggest the 
involvement of HMGB1 in the determination of the metastatic potential of 
CSCC cells (Sun et al. 2016). 
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In addition to the different possible mechanisms that link HMGA1 and 
autophagy, we have to discuss the complex role of autophagy in cancer, to 
hypothesize which can be the implications of HMGA1-mediated autophagy 
regulation in cancer cells. In fact, even though autophagy may promote the 
early phases of tumor growth, allowing survival of cancer cells under stress 
conditions, such as hypoxia, and providing new energy sources, it represents 
also a cell-autonomous mechanism of tumor suppression for its role in 
maintaining organelle homeostasis, reducing oxidative stress and inducing cell 
death (Matthew et al. 2007). In particular, stimulation of autophagy by 
exogenous and endogenous stress, including chemotherapy, radiotherapy and 
hypoxia, reduces cancer cell survival. However, autophagy impairment and 
resistance to autophagic cell death are features frequently acquired during 
cancer progression accounting, together with resistance to apoptosis, for 
enhanced cancer cell survival and chemoresistance (Sui et al. 2013). Therefore, 
we can speculate that HMGA1 overexpression may contribute to cancer 
progression by preventing cancer cells from dying for autophagy.  
It is noteworthy that HMGA protein overexpression plays a critical role 
in inhibiting apoptosis mainly impairing p53-mediated regulation of apoptotic 
genes (Frasca et al. 2006). Intriguingly, since it has been reported that p53 
positively regulates ULK1 expression (Gao et al. 2011), we can speculate that 
HMGA1 and p53 can regulate the expression of the same autophagy-related 
genes in an opposite way, as already described for apoptosis-related genes 
(Esposito et al. 2010). Moreover, resistance to autophagic cell death has also 
been correlated to other cellular processes in which HMGA1 proteins are 
involved, such as chromosomal instability and impairment of DNA repair 
(Palmieri et al. 2011, Matthew et al. 2007, Gao et al. 2011, Czarny et al. 2015). 
Therefore, we can envisage the possibility that HMGA1 would enhance the 
survival of cancer cell and, thereby, cancer progression by inhibiting, at the 
same time, autophagy and apoptosis. Moreover, it is worth of note to consider 
the possible interplay among HMGA1, autophagy and genomic instability in 
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cancer cells. In fact, on one hand, we have demonstrated that HMGA1 is able 
to impair DNA repair mechanisms and to induce chromosome instability, and, 
on the other hand, it is known that autophagy is able to counteract the 
accumulation of DNA damage and chromosomal abnormalities in cancer cells. 
In fact, autophagy-deficient cancer cells display both high levels of DNA 
damage, probably because of malfunctioning organelles, accumulation of toxic 
protein aggregates, oxidative stress, failure of energy homeostasis, and 
accumulation of aneuploidy. Despite the reduced cellular fitness caused by 
deficient autophagy, the superior adaptation due to increased mutation rate 
might be the key advantage that promotes tumorigenesis, because high 
mutational rate and genomic instability allow cancer cells to quickly adapt to 
environmental changes and to become resistant to chemo- and/or radiotherapy 
(Mathew et al. 2007). On the basis of these considerations, we can speculate 
that the inhibition of autophagy induced by HMGA1 is another mechanism, 
together with SAC and   impairment, by which HMGA1 may contribute to 
genomic instability and, eventually, cancer progression. 
Homeodomain-interacting protein kinase 2 (HIPK2) is a Ser/Thr kinase 
involved in several biological processes, such as cell proliferation, apoptosis 
and DNA damage response, that phosphorylates several transcription factors or 
co-regulators modulating their activity. HIPK2 binds and phosphorylate 
HMGA1 affecting its ability to bind DNA (Pierantoni et al. 2001, Zhang and 
Wang 2007). To evaluate the in vivo effects of the contemporary genetic 
ablation of both Hmga1 and Hipk2, we have crossed Hmga1 and Hipk2 KO 
mice obtaining double KO mice (DKO). Interestingly, Hmga1 and Hipk2 DKO 
display an immature pulmonary phenotype, characterized by collapsed 
immature sac-like alveoli, which causes respiratory failure and perinatal 
mortality (Gerlini et al., unpublished data), strongly resembling the phenotype 
of Ulk1 and Ulk2 DKO that is due to defective autophagy (Cheong et al. 2013). 
These preliminary data suggest that HMGA1 and HIPK2 might cooperate in 
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the regulation of autophagy during lung development, but need to be confirmed 
by further studies. 
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6. Conclusions 
In summary, the data reported here clearly evidence that depletion of 
HMGA1 increases autophagy by, at least in part, negatively regulating the 
expression of ULK genes, coding for master regulators of autophagy induction. 
These results would implicate that overexpression of HMGA1 may be a cause 
of autophagy impairment in cancer cells, and that autophagy inhibition may be 
a novel mechanism by which HMGA1 overexpression enhances survival of 
cancer cells and contributes to cancer progression, further supporting possible 
innovative antineoplastic therapies based on the inactivation of HMGA1 
functions.  
In order to rationalize the complexities of neoplastic diseases, Hanahan 
and Weimberg, in a very famous paper published in 2000 and updated in 2011, 
defined the so called “hallmarks of cancer”: six biological capabilities acquired 
during the multistep development of human tumors that account for the 
“behaviour” of cancer cells (Hanahan and Weimberg 2000, Hanahan and 
Weimberg 2011). The hallmarks of cancer include sustaining proliferative 
signaling, evading growth suppressors, resisting cell death, enabling replicative 
immortality, inducing angiogenesis, activating invasion and metastasis, 
reprogramming energy metabolism and evading immune destruction (Hanahan 
and Weimberg 2000, Hanahan and Weimberg 2011). Genomic instability is 
reputed the key determinant for the acquisition of hallmarks of cancer, and it is 
emerging that also autophagy impairment concurs to the establishment of some 
of these features. For these reasons, the findings that I have obtained during my 
PhD activity, demonstrating the involvement of HMGA1 both in the induction 
of genomic instability and in the regulation of the autophagic process, 
corroborate the idea that this protein has a central role in cancer initiation and 
progression and point out that HMGA1 may concur in the acquisition of almost 
all the hallmarks of cancer.   
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Synopsis of publications 
 
1. Pierantoni GM*, Conte A*, Rinaldo C, Tornincasa M, Gerlini R, Federico 
A, Valente D, Medico E, Fusco A. Deregulation of HMGA1 expression 
induces chromosome instability through regulation of spindle assembly 
checkpoint genes. Oncotarget. 2015 Jul 10;6(19):17342-53. (*Co-first 
authors) 
The mitotic spindle assembly checkpoint (SAC) is an essential control system 
of the cell cycle that contributes to mantain the genomic stability of eukaryotic 
cells. SAC genes expression is often deregulated in cancer cells, leading to 
checkpoint impairment and chromosome instability. The mechanisms 
responsible for the transcriptional regulation and deregulation of these genes 
are still largely unknown. Herein we identify the nonhistone architectural 
nuclear proteins High Mobility Group A1 (HMGA1), whose overexpression is 
a feature of several human malignancies and has a key role in cancer 
progression, as transcriptional regulators of SAC genes expression. In 
particular, we show that HMGA1 proteins are able to increase the expression 
of the SAC genes Ttk, Mad2l1, Bub1 and Bub1b, binding to their promoter 
regions. Consistently, HMGA1-depletion induces SAC genes downregulation 
associated to several mitotic defects. In particular, we observed a high number 
of unaligned chromosomes in metaphase, a reduction of prometaphase time, a 
delay of anaphase, a higher cytokinesis time and a higher percentage of 
cytokinesis failure by using live-cell microscopy. Finally, a significant direct 
correlation between HMGA1 and SAC genes expression was detected in 
human colon carcinomas indicating a novel mechanism by which HMGA1 
contributes to cancer progression. 
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2. Conte A, Pierantoni GM. Regulation of HIPK Proteins by MicroRNAs. 
Microrna. 2016;4(3):148-57 
 
The homeodomain-interacting protein kinase (HIPK) family consists of four 
evolutionarily conserved and highly related nuclear serine/threonine kinases of 
recent discovery. They interact with homeobox proteins and other transcription 
factors, as well as transcriptional coactivators or corepressors depending on the 
cellular context. HIPK proteins are sensors for various extracellular stimuli, 
which control key cellular functions such as signal transduction to downstream 
effectors that regulate apoptosis, embryonic development, DNA-damage 
response, and cellular proliferation. Thus, HIPKs are involved in proliferative 
diseases such as cancer and fibrosis. mRNA levels and protein stability tightly 
regulate expression levels of HIPKs. Here, we review recent works 
investigating the regulation of HIPKs expression by microRNAs (miRNAs) 
that are involved in the control of cell proliferation, sensitivity to 
chemotherapeutic drugs, epithelial-mesenchymal transition, and glucose-
stimulated insulin secretion. It appears that HIPK family members, and their 
related miRNAs, may be considered as novel therapeutic targets for treating 
cancer, renal fibrosis and type 2 diabetes. 
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3. Anzilotti S, Tornincasa M, Gerlini R, Conte A, Brancaccio P Cuomo O, 
Bianco G, Fusco A, Annunziato L, Pignataro G, and Pierantoni GM. Genetic 
ablation of homeodomain interacting protein kinase 2 (HIPK2) selectively 
induces apoptosis of cerebellar Purkinje cells during adulthood and 
generates an ataxic-like phenotype. Cell Death Dis. 2015 Dec 3;6:e2004 
 
Homeodomain-interacting protein kinase 2 (HIPK2) is a multitalented 
coregulator of an increasing number of transcription factors and cofactors 
involved in cell death and proliferation in several organs and systems. As 
Hipk2(-/-) mice show behavioral abnormalities consistent with cerebellar 
dysfunction, we investigated whether Hipk2 is involved in these neurological 
symptoms. To this aim, we characterized the postnatal developmental 
expression profile of Hipk2 in the brain cortex, hippocampus, striatum, and 
cerebellum of mice by real-time PCR, western blot analysis, and 
immunohistochemistry. Notably, we found that whereas in the brain cortex, 
hippocampus, and striatum, HIPK2 expression progressively decreased with 
age, that is, from postnatal day 1 to adulthood, it increased in the cerebellum. 
Interestingly, mice lacking Hipk2 displayed atrophic lobules and a visibly 
smaller cerebellum than did wild-type mice. More important, the cerebellum of 
Hipk2 (-/-) mice showed a strong reduction in cerebellar Purkinje neurons 
during adulthood. Such reduction is due to the activation of an apoptotic 
process associated with a compromised proteasomal function followed by an 
unpredicted accumulation of ubiquitinated proteins. In particular, Purkinje cell 
dysfunction was characterized by a strong accumulation of ubiquitinated β-
catenin. Moreover, our behavioral tests showed that Hipk2 (-/-) mice displayed 
muscle and balance impairment, indicative of Hipk2 involvement in cerebellar 
function. Taken together, these results indicate that Hipk2 exerts a relevant role 
in the survival of cerebellar Purkinje cells and that Hipk2 genetic ablation 
generates cerebellar dysfunction compatible with an ataxic-like phenotype. 
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4. Conte A, Procaccini C, Iannelli P, Kisslinger A, De Amicis F, Pierantoni 
GM, Mancini FP, Matarese G and Tramontano D. Effects of Resveratrol on 
p66Shc phosphorylation in cultured prostate cells. Transl Medi UniSa 2015, 
13(8): 47-58  
 
There is increasing evidence that diet plays a crucial role in age-related 
diseases and cancer. Oxidative stress is a conceivable link between diet and 
diseases, thus food antioxidants, counteracting the damage caused by 
oxidation, are potential tools for fight age-related diseases and cancer. 
Resveratrol (RSV), a polyphenolic antioxidant from grapes, has gained 
enormous attention particularly because of its ability to induce growth arrest 
and apoptosis in cancer cells, and it has been proposed as both chemo- 
preventive and therapeutic agent for cancer and other diseases. Even though 
the effects of RSV have been studied in prostate cancer cells and animal 
models, little is known about its effects on normal cells and tissues. To address 
this issue, we have investigated the effects of RSV on EPN cells, a human non-
transformed prostate cell line, focusing on the relationship between RSV and 
p66Shc, a redox enzyme whose activities strikingly intersect those of RSV. 
p66Shc activity is regulated by phosphorylation of serine 36 (Ser36) and has 
been related to mitochondrial oxidative stress, apoptosis induction, regulation 
of cell proliferation and migration. Here we show that RSV inhibits adhesion, 
proliferation and migration of EPN cells, and that these effects are associated 
to induction of dose- and time-dependent p66Shc-Ser36 phosphorylation and 
ERK1/2 de-phosphorylation. Moreover, we found that RSV is able to activate 
also p52Shc, another member of the Shc protein family. These data show that 
RSV affects non-transformed prostate epithelial cells and suggest that Shc 
proteins may be key contributors of RSV effects on prostate cells.  
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5. Pierantoni GM*, Conte A*, Rinaldo C, Tornincasa M, Gerlini R, Valente D, 
Izzo A, Fusco A. Hmga1 null mouse embryonic fibroblasts display 
downregulation of spindle assembly checkpoint gene expression associated 
to nuclear and karyotypic abnormalities. Cell Cycle. 2016 Feb 18:0; 15(6):812-
818  (*Co-first authors) 
 
The High Mobility Group A1 proteins (HMGA1) are nonhistone chromatinic 
proteins with a critical role in development and cancer. We have recently 
reported that HMGA1 proteins are able to increase the expression of spindle 
assembly checkpoint (SAC) genes, thus impairing SAC function and causing 
chromosomal instability in cancer cells. Moreover, we found a significant 
correlation between HMGA1 and SAC genes expression in human colon 
carcinomas. Here, we report that mouse embryonic fibroblasts null for the 
Hmga1 gene show downregulation of Bub1, Bub1b, Mad2l1 and Ttk SAC 
genes, and present several features of chromosomal instability, such as nuclear 
abnormalities, binucleation, micronuclei and karyotypic alterations. 
Interestingky, also MEFs carrying only one impaired Hmga1 allele present 
karyotypic alterations. These results indicate that HMGA1 proteins regulate 
SAC genes expression and, thereby, genomic stability also in embryonic cells. 
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